Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 15 |
| List of Tables | 14 | 2 |
| List of Figures | 16 | 1 |
| Introduction | 17 | 1 |
| Global Markets Direct Report Coverage | 17 | 1 |
| Graft Versus Host Disease (GVHD) Overview | 18 | 1 |
| Therapeutics Development | 19 | 2 |
| Pipeline Products for Graft Versus Host Disease (GVHD) Overview | 19 | 1 |
| Pipeline Products for Graft Versus Host Disease (GVHD) Comparative Analysis | 20 | 1 |
| Graft Versus Host Disease (GVHD) Therapeutics under Development by Companies | 21 | 5 |
| Graft Versus Host Disease (GVHD) Therapeutics under Investigation by Universities/Institutes | 26 | 2 |
| Graft Versus Host Disease (GVHD) Pipeline Products Glance | 28 | 4 |
| Late Stage Products | 28 | 1 |
| Clinical Stage Products | 29 | 1 |
| Early Stage Products | 30 | 1 |
| Unknown Stage Products | 31 | 1 |
| Graft Versus Host Disease (GVHD) Products under Development by Companies | 32 | 5 |
| Graft Versus Host Disease (GVHD) Products under Investigation by Universities/Institutes | 37 | 1 |
| Graft Versus Host Disease (GVHD) Companies Involved in Therapeutics Development | 38 | 60 |
| AbbVie Inc | 38 | 1 |
| AbGenomics International, Inc. | 39 | 1 |
| Actelion Ltd | 40 | 1 |
| Alexion Pharmaceuticals Inc | 41 | 1 |
| Amunix Operating Inc. | 42 | 1 |
| Apceth GmbH &Co. KG | 43 | 1 |
| arGEN-X BV | 44 | 1 |
| Athersys, Inc. | 45 | 1 |
| Bellicum Pharmaceuticals, Inc. | 46 | 1 |
| Bio-Cancer Treatment International Limited | 47 | 1 |
| Biogen Inc | 48 | 1 |
| Bristol-Myers Squibb Company | 49 | 1 |
| Cantex Pharmaceuticals, Inc. | 50 | 1 |
| Capricor Therapeutics, Inc. | 51 | 1 |
| Cell2B S.A. | 52 | 1 |
| CellECT Bio, Inc. | 53 | 1 |
| Cynata Therapeutics Limited | 54 | 1 |
| Cytodyn Inc. | 55 | 1 |
| Dompe Farmaceutici S.p.A. | 56 | 1 |
| Dr. Falk Pharma GmbH | 57 | 1 |
| Escape Therapeutics, Inc. | 58 | 1 |
| F. Hoffmann-La Roche Ltd. | 59 | 1 |
| Fate Therapeutics, Inc. | 60 | 1 |
| Generon (Shanghai) Corporation Ltd. | 61 | 1 |
| Gilead Sciences, Inc. | 62 | 1 |
| GlaxoSmithKline Plc | 63 | 1 |
| Idera Pharmaceuticals, Inc. | 64 | 1 |
| ImmuNext, Inc. | 65 | 1 |
| Immunomedics, Inc. | 66 | 1 |
| Incyte Corporation | 67 | 1 |
| Kadmon Corporation, LLC | 68 | 1 |
| Kamada Ltd. | 69 | 1 |
| Kiadis Pharma N.V. | 70 | 1 |
| Kymab Limited | 71 | 1 |
| Kyorin Pharmaceutical Co., Ltd. | 72 | 1 |
| MacroGenics, Inc. | 73 | 1 |
| Mallinckrodt Plc | 74 | 1 |
| Medsenic | 75 | 1 |
| Mesoblast Limited | 76 | 1 |
| Millennium Pharmaceuticals Inc | 77 | 1 |
| Neopharm Ltd. | 78 | 1 |
| Nohla Therapeutics Inc. | 79 | 1 |
| Novartis AG | 80 | 1 |
| OncoImmune, Inc. | 81 | 1 |
| OSE Immunotherapeutics | 82 | 1 |
| Pharmicell Co., Ltd. | 83 | 1 |
| REGiMMUNE Corporation | 84 | 1 |
| Rigel Pharmaceuticals, Inc. | 85 | 1 |
| Sarepta Therapeutics, Inc. | 86 | 1 |
| Seattle Genetics, Inc. | 87 | 1 |
| Seres Therapeutics, Inc. | 88 | 1 |
| Sigmoid Pharma Limited | 89 | 1 |
| Spherium Biomed S.L. | 90 | 1 |
| Takeda Pharmaceutical Company Limited | 91 | 1 |
| Targazyme, Inc. | 92 | 1 |
| Therapix Biosciences Ltd. | 93 | 1 |
| Tobira Therapeutics, Inc. | 94 | 1 |
| Vault Pharma Inc. | 95 | 1 |
| Xenikos B.V. | 96 | 1 |
| ZIOPHARM Oncology, Inc. | 97 | 1 |
| Graft Versus Host Disease (GVHD) Therapeutics Assessment | 98 | 14 |
| Assessment by Monotherapy Products | 98 | 1 |
| Assessment by Combination Products | 99 | 1 |
| Assessment by Target | 100 | 4 |
| Assessment by Mechanism of Action | 104 | 4 |
| Assessment by Route of Administration | 108 | 2 |
| Assessment by Molecule Type | 110 | 2 |
| Drug Profiles | 112 | 266 |
| abatacept Drug Profile | 112 | 5 |
| AbGn-168H Drug Profile | 117 | 2 |
| AGS-499 Drug Profile | 119 | 1 |
| aldesleukin Drug Profile | 120 | 2 |
| Alecmestencel-L Drug Profile | 122 | 1 |
| alpha-1 proteinase inhibitor (human) Drug Profile | 123 | 4 |
| ALXN-1007 Drug Profile | 127 | 2 |
| AMX-342 Drug Profile | 129 | 1 |
| anti-thymocyte globulin (rabbit) Drug Profile | 130 | 2 |
| Antibodies to Antagonize CD40L for Autoimmune Diseases and GVHD Drug Profile | 132 | 1 |
| Antisense Oligonucleotide to Inhibit TLRs for Systemic Lupus Erythematosus and Graft Versus Host Disease Drug Profile | 133 | 1 |
| ARGX-115 Drug Profile | 134 | 1 |
| arsenic trioxide Drug Profile | 135 | 1 |
| ATIR-101 Drug Profile | 136 | 4 |
| BCT-200 Drug Profile | 140 | 1 |
| begelomab Drug Profile | 141 | 1 |
| Biologic to Activate IL-2 for Graft Versus Host Disease Drug Profile | 142 | 1 |
| Biologics for Graft Versus Host Disease Drug Profile | 143 | 1 |
| bortezomib Drug Profile | 144 | 8 |
| BPX-501 Drug Profile | 152 | 4 |
| brentuximab vedotin Drug Profile | 156 | 24 |
| budesonide Drug Profile | 180 | 3 |
| cannabidiol Drug Profile | 183 | 1 |
| CAP-2003 Drug Profile | 184 | 1 |
| CD-24Fc Drug Profile | 185 | 1 |
| Cell Therapy for Graft Versus Host Disease Drug Profile | 186 | 1 |
| Cell Therapy for Graft-Versus Host Disease Drug Profile | 187 | 1 |
| Cellgram for Graft Versus Host Disease Drug Profile | 188 | 1 |
| Cellular Immunotherapy for Acute Graft Versus Host Disease Drug Profile | 189 | 1 |
| Cellular Immunotherapy for Autoimmune Diseases and Transplantation Drug Profile | 190 | 2 |
| Cellular Immunotherapy for Graft Versus Host Disease Drug Profile | 192 | 1 |
| Cellular Immunotherapy for Graft Versus Host Disease Drug Profile | 193 | 1 |
| Cellular Immunotherapy for Graft Versus Host Disease Drug Profile | 194 | 1 |
| Cellular Immunotherapy for Graft Versus Host Disease Drug Profile | 195 | 1 |
| Cellular Immunotherapy for Graft Versus Host Disease Drug Profile | 196 | 1 |
| Cellular Immunotherapy for Graft Versus Host Disease Drug Profile | 197 | 1 |
| Cellular Immunotherapy for Graft Versus Host Disease Drug Profile | 198 | 1 |
| Cellular Immunotherapy for Graft Versus Host Disease and Multiple Myeloma Drug Profile | 199 | 1 |
| cenicriviroc mesylate Drug Profile | 200 | 7 |
| CRCBT-080004 Drug Profile | 207 | 1 |
| CX-01 Drug Profile | 208 | 2 |
| cyclosporine CR + cyclosporine IR Drug Profile | 210 | 1 |
| CYP-001 Drug Profile | 211 | 2 |
| entospletinib Drug Profile | 213 | 2 |
| F-652 Drug Profile | 215 | 1 |
| FR-104 Drug Profile | 216 | 3 |
| Ha-7 Drug Profile | 219 | 1 |
| ibrutinib Drug Profile | 220 | 25 |
| ImmuneSafe Drug Profile | 245 | 1 |
| ImmuStem Drug Profile | 246 | 1 |
| IMO-8400 Drug Profile | 247 | 6 |
| IT-603 Drug Profile | 253 | 1 |
| IT-901 Drug Profile | 254 | 1 |
| itacitinib adipate Drug Profile | 255 | 3 |
| KD-025 Drug Profile | 258 | 4 |
| KRP-203 Drug Profile | 262 | 2 |
| KY-1005 Drug Profile | 264 | 1 |
| MAX-16H5 Drug Profile | 265 | 1 |
| MesoStem Drug Profile | 266 | 1 |
| methoxsalen Drug Profile | 267 | 2 |
| MGD-010 Drug Profile | 269 | 2 |
| milatuzumab Drug Profile | 271 | 2 |
| Monoclonal Antibody to Inhibit CD3 for Cardiovascular, CNS, Gastrointestinal, Immunological, Infectious and Metabolic Diseases Drug Profile | 273 | 2 |
| natalizumab Drug Profile | 275 | 4 |
| nilotinib Drug Profile | 279 | 6 |
| obinutuzumab Drug Profile | 285 | 7 |
| OCU-300 Drug Profile | 292 | 1 |
| Oligonucleotide to Inhibit NFAT1 for GVHD Drug Profile | 293 | 1 |
| panobinostat Drug Profile | 294 | 8 |
| PF-05285401 Drug Profile | 302 | 10 |
| ponesimod Drug Profile | 312 | 2 |
| Preimplantation Factor Drug Profile | 314 | 1 |
| PRO-140 Drug Profile | 315 | 8 |
| ProTmune Drug Profile | 323 | 2 |
| R-348 Drug Profile | 325 | 2 |
| Recombinant Protein for Graft Versus Host Disease and Autoimmune Disorders Drug Profile | 327 | 1 |
| Recombinant Protein to Antagonize CCR8 for Graft Versus Host Disease and Multiple Sclerosis Drug Profile | 328 | 1 |
| Recombinant Protein to Inhibit ILT3 for Graft Versus Host Disease Drug Profile | 329 | 1 |
| remestemcel-L Drug Profile | 330 | 5 |
| reparixin Drug Profile | 335 | 3 |
| RGI-2001 Drug Profile | 338 | 2 |
| RO-2959 Drug Profile | 340 | 1 |
| rovalpituzumab tesirine Drug Profile | 341 | 2 |
| ruxolitinib phosphate Drug Profile | 343 | 11 |
| S-Graft Drug Profile | 354 | 1 |
| SER-155 Drug Profile | 355 | 1 |
| Small Molecule for Autoimmune Disorders, Graft Versus Host Disease and Hemophagocytic Lymphohistiocytosis Drug Profile | 356 | 1 |
| Small Molecule to Inhibit Protein Kinase C Theta for Immunological Disorders and Multiple Sclerosis Drug Profile | 357 | 1 |
| Small Molecules to Inhibit SHIP1 for Oncology and Immunology Drug Profile | 358 | 1 |
| Small Molecules to Selectively Inhibit ROCK2 for Autoimmune Disorders Drug Profile | 359 | 1 |
| sonidegib phosphate Drug Profile | 360 | 4 |
| SP-12008 Drug Profile | 364 | 1 |
| SYGN-305 Drug Profile | 365 | 1 |
| Synthetic Peptide to Antagonize VIPR for Cytomegalovirus Infection and Graft Versus Host Disease Drug Profile | 366 | 1 |
| T-Guard Drug Profile | 367 | 2 |
| TZ-101 Drug Profile | 369 | 3 |
| vedolizumab Drug Profile | 372 | 4 |
| VPI-101 Drug Profile | 376 | 1 |
| ZL-1101 Drug Profile | 377 | 1 |
| Graft Versus Host Disease (GVHD) Dormant Projects | 378 | 5 |
| Graft Versus Host Disease (GVHD) Discontinued Products | 383 | 1 |
| Graft Versus Host Disease (GVHD) Product Development Milestones | 384 | 11 |
| Featured News &Press Releases | 384 | 1 |
| Aug 29, 2016: European Commission Grants Orphan Drug Designation to ALXN1007 for the Treatment of Patients with Graft-Versus-Host Disease | 384 | 1 |
| Jun 21, 2016: Cynata Prepares for Phase 1 Clinical Trial | 384 | 1 |
| Jun 10, 2016: Alexion Pharmaceuticals Presented data on ALXN1007 at 21st Congress of the European Hematology Association | 385 | 1 |
| Jun 02, 2016: Kiadis Pharma announces its decision to file for marketing authorization with the European Medicines Agency (EMA) for ATIR101 in blood cancers | 385 | 2 |
| May 19, 2016: Researchers to Present Additional Data, Including Late-Breaking Results on ALXN1007 in Patients with GI-GVHD at EHA Annual Congress | 387 | 1 |
| May 18, 2016: Kiadis Pharma presents multiple sets of data at the International Society for Cellular Therapy 2016 Annual Meeting | 387 | 2 |
| Apr 07, 2016: Cynata Reports Compelling Results from Pre-clinical Stem Cell Study in Graft-versus-Host Disease (GvHD) | 389 | 1 |
| Apr 04, 2016: Kiadis Pharma presents positive data on the primary endpoint of its single dose Phase II trial with ATIR101 | 389 | 2 |
| Mar 29, 2016: Kiadis Pharma to host a webcast of the full dataset on the primary endpoint of its single-dose Phase II trial with ATIR101 | 391 | 1 |
| Mar 21, 2016: Kadmon Announces Publication of Data Demonstrating the Potential of ROCK2 Inhibition to Treat Chronic Graft-Versus-Host Disease | 391 | 1 |
| Feb 24, 2016: First Allogeneic Cell Therapy Product Launched in Japan by Mesoblast Licensee | 392 | 1 |
| Feb 22, 2016: Mesoblast s Cell Therapy Increases Survival in Children With Acute Graft Versus Host Disease | 393 | 1 |
| Feb 16, 2016: Launch of TEMCELL HS Inj, World s First Mesenchymal Stem Cell Product for GVHD Treatment, and Commencement of Operation of Ultra-Low Cold Chain System | 393 | 1 |
| Jan 28, 2016: Cynata Receives Favourable Advice from UK Regulatory Authority | 394 | 1 |
| Appendix | 395 | 2 |
| Methodology | 395 | 1 |
| Coverage | 395 | 1 |
| Secondary Research | 395 | 1 |
| Primary Research | 395 | 1 |
| Expert Panel Validation | 395 | 1 |
| Contact Us | 395 | 1 |
| Disclaimer | 396 | 1 |